human milk oligosaccharides (HMOs)

DSM approves 3-FL ingredient for increased HMO access

Royal DSM, a global science-based company active in Health, Nutrition and Bioscience, have announced that its newly developed human milk oligosaccharide (HMO) – 3-fucosyllactose (3-FL) – has been approved as an ingredient in food applications in the US and Australia.

Dairy science, Regulatory

HMO study paves the way for developing next-generation infant formula

HMOs can, in some cases, be secreted in very high concentrations, and still be safe and well-tolerated by infants, according to a new study by Chr. Hansen.

Dairy science

Chr Hansen publishes first scientific study of HMOs mix in natural concentrations in infant formula

Chr Hansen has conducted a scientific study of an infant formula containing the five most abundant Human Milk Oligosaccharides at a concentration which resembles that which is naturally found in mother’s milk.

Dairy science

Chr Hansen announces acquisition of Jennewein

By entering into the acquisition agreement, Chr Hansen enters and plans to lead in the human milk oligosaccharides (HMO) market.

Business & trade, Ingredients

Where innovation leads

The advancement in infant formulas is so profound that the formulas of today are a far cry from what passed for formula even a decade ago.

Ingredients

DSM to acquire Glycom to accelerate growth in Early Life Nutrition

With the acquisition of Glycom, DSM adds HMOs to its portfolio, a novel high-growth ingredient for next generation early life nutrition solutions.

Business & trade, Dairy science

DuPont and Lonza join to produce HMOs

DuPont Nutrition & Health and Lonza Specialty Ingredients have announced an agreement under which Lonza will manufacture and supply Care4U 2’-FL – a human milk oligosaccharide (HMOs).

Business & trade, Dairy processing, Dairy science, Ingredients